One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin
- Authors: Daniel B. Brown, Carin F. Gonsalves, Charles J. Yeo, Agnes K. Witkiewicz, Brian I. Carr
Published online on: Wednesday, September 1, 2010
- Pages: 767-769
- DOI: 10.3892/or_00000919
While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.